2020-26487. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Records; Electronic Signatures  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

    DATES:

    Submit written comments (including recommendations) on the collection of information by December 31, 2020.

    ADDRESSES:

    To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/​public/​do/​PRAMain. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0303. Also include the FDA docket number found in brackets in the heading of this document.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, PRAStaff@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

    Electronic Records; Electronic Signatures—21 CFR Part 11

    OMB Control Number 0910-0303—Extension

    This information collection supports FDA regulations in part 11 (21 CFR part 11), which govern criteria for acceptance of electronic records, electronic signatures, and handwritten signatures executed to electronic records as equivalent to paper records. Under these regulations, records and reports may be submitted to us electronically provided that we have stated our ability to accept the records electronically in an Agency-established public docket and that the other requirements of part 11 are met.

    The recordkeeping provisions in §§ 11.10, 11.30, 11.50, and 11.300 (21 CFR 11.10, 11.30, 11.50, and 11.300) require the following standard operating procedures to ensure appropriate use of and precautions for systems using electronic records and signatures: (1) § 11.10 specifies procedures and controls for persons who use closed systems to create, modify, maintain, or transmit electronic records; (2) § 11.30 specifies procedures and controls for persons who use open systems to create, modify, maintain, or transmit electronic records; (3) § 11.50 specifies procedures and controls for persons who use electronic signatures; and (4) § 11.300 specifies controls to ensure the security and integrity of electronic signatures based upon use of identification codes in combination with passwords. The reporting provision (§ 11.100) requires persons to certify to us in writing that they will regard electronic signatures used in their systems as the legally binding equivalent of traditional handwritten signatures.

    The burden created by the information collection provision of this regulation is a one-time burden associated with the creation of standard operating procedures, validation, and certification. We anticipate that the use of electronic media will substantially reduce the paperwork burden associated with maintaining FDA-required records. The respondents are businesses and other for-profit organizations, State or local governments, Federal Agencies, and nonprofit institutions.

    To assist respondents with the information collection we have developed the guidance document entitled “Guidance for Industry: Part 11, Electronic Records; Electronic Signatures—Scope and Application,” available on our website at https://www.fda.gov/​media/​75414/​download. While we do not believe the guidance creates any attendant burden, it describes the Agency's thinking regarding persons who, in fulfillment of a requirement in a statute or another part of FDA's regulations to maintain records or submit information to FDA, have chosen to maintain the records or submit designated information electronically and, as a result, have become subject to part 11. Part 11 applies to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under any records requirements set forth in Agency regulations. Part 11 also Start Printed Page 77224applies to electronic records submitted to the Agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, even if such records are not specifically identified in Agency regulations (§ 11.1).

    In the Federal Register of August 13, 2020 (85 FR 49381), we published a 60-day notice requesting public comment on the proposed collection of information. One comment was received but was not responsive to the information collection topics solicited.

    We estimate the burden of this collection of information as follows:

    Table 1—Estimated Annual Reporting Burden 1

    21 CFR sectionNumber of respondentsNumber of responses per respondentTotal annual responsesAverage burden per responseTotal hours
    § 11.1004,50014,50014,500
    1 There are no capital costs or operating and maintenance costs associated with this collection of information.

    Table 2—Estimated Annual Recordkeeping Burden 1

    21 CFR sectionNumber of recordkeepersNumber of record per recordkeepersTotal annual recordsAverage burden per recordkeepingTotal hours
    § 11.102,50012,5002050,000
    § 11.302,50012,5002050,000
    § 11.504,50014,5002090,000
    § 11.3004,50014,5002090,000
    Total280,000
    1 There are no capital costs or operating and maintenance costs associated with this collection of information.

    Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

    Start Signature

    Dated: November 23, 2020.

    Lauren K. Roth,

    Acting Principal Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2020-26487 Filed 11-30-20; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
12/01/2020
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2020-26487
Dates:
Submit written comments (including recommendations) on the collection of information by December 31, 2020.
Pages:
77223-77224 (2 pages)
Docket Numbers:
Docket No. FDA-2011-N-0076
PDF File:
2020-26487.pdf
Supporting Documents:
» Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
» Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Records; Electronic Signatures
» Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Records; Electronic Signatures
» Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals; Correction
» Agency Information Collection Activities; Proposals, Submissions, and Approvals
» Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Signatures
» Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Records; Electronic Signatures
» Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Records; Electronic Signatures
» Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Records; Electronic Signatures
» Agency Information Collection Activities; Proposals, Submissions, and Approvals: Electronic Records; Electronic Signatures